Zobrazeno 1 - 10
of 186
pro vyhledávání: '"Russel, Burge"'
Autor:
Alexander Egeberg, Jason E. Hawkes, Najwa Somani, Russel Burge, Kyoungah See, Gaia Gallo, Missy McKean-Matthews, Melinda Gooderham, George Han, April Armstrong
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 4, Pp 1007-1018 (2024)
Abstract Introduction Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is approved for the treatment of moderate-to-severe plaque psoriasis. Since scalp psoriasis can be burdensome and challenging to treat wit
Externí odkaz:
https://doaj.org/article/2172459873774bdcb1e836294768df9a
Autor:
Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Yunyang Zhao, Julie McCormack, Miriam Kimel, Joseph F. Merola
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 8, Pp 1831-1846 (2023)
Abstract Introduction Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s pers
Externí odkaz:
https://doaj.org/article/114f099f9c514b8f96ecb4ac00b347b4
Autor:
Jennifer Soung, Jennifer C. Cather, Melinda Gooderham, Caitriona Ryan, Najwa Somani, Meghan Feely, Kyoungah See, Russel Burge, Mohamed Elrayes, Gaia Gallo, April W. Armstrong
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 2, Pp 282-292 (2023)
Abstract Background People with genital psoriasis may avoid close social interactions (hugs, handshakes, kisses, touching others, or being touched), which can have a significant impact on quality of life. Ixekizumab, an interleukin 17A antagonist, de
Externí odkaz:
https://doaj.org/article/ffcd1adcd24c46c0986747258116f460
Autor:
Craig Leonardi, Rei Tao, Solmaz Setayeshgar, Sisi Wang, Russel Burge, Baojin Zhu, William N. Malatestinic
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 4, Pp 2278-2284 (2022)
Objective To assess treatment patterns of Ixekizumab (IXE) and evaluate the speed of onset and long-term clinical and quality-of-life outcomes among a subset of patients who switched from adalimumab (ADA) and secukinumab (SEC) to IXE in a real-world
Externí odkaz:
https://doaj.org/article/e4a7ae5f16094b41bebcbf0325e28bc5
Autor:
Mona Shahriari, Ryan W. Harrison, Russel Burge, Chen-Yen Lin, William N. Malatestinic, Orin M. Goldblum, Robert R. McLean, Margaux M. Crabtree, Jacqueline O’Brien, Elsie L. Grace, Mwangi J. Murage
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 3, Pp 1538-1546 (2022)
Objectives There is limited real-world evidence on using ixekizumab in psoriasis patients. Therefore, we characterized patients with psoriasis initiating ixekizumab and report 6-month changes in disease and patient-reported outcomes. Methods Adult pa
Externí odkaz:
https://doaj.org/article/494c7f60c2c548fa9a3df546092dbc63
Autor:
Wayne Gulliver, Michelle Penney, Rebecca Power, Susanne Gulliver, Sonia Montmayeur, Russel Burge
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 1, Pp 354-360 (2022)
Introduction Data on real-world experiences for patients treated with ixekizumab is currently limited. Objectives Describe characteristics of ixekizumab-treated psoriasis patients and provide evidence of clinical outcomes using disease severity score
Externí odkaz:
https://doaj.org/article/9300a342f90a40fd8727e41cd1f9b6fb
Autor:
Mwangi J. Murage, Adrienne M. Gilligan, Oth Tran, Orin Goldblum, Russel Burge, Chen-Yen Lin, Abrar Qureshi
Publikováno v:
Journal of Dermatological Treatment, Vol 32, Iss 1, Pp 56-63 (2021)
Objectives: To describe ixekizumab treatment patterns, all-cause healthcare utilization, and costs among psoriasis patients. Methods: Adults diagnosed with psoriasis having ≥1 ixekizumab claim were selected from MarketScan® databases between March
Externí odkaz:
https://doaj.org/article/75b2556b51a84985b9ab65aa8f8035bb
Autor:
Alexander Egeberg, Yuki M F Andersen, Amy M DeLozier, Lea Nymand, Russel Burge, Emily Edson-Heredia
Publikováno v:
BMJ Open, Vol 12, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/6ee1a37846c0495696817a5059056c16
Publikováno v:
Dermatology and Therapy, Vol 10, Iss 6, Pp 1397-1404 (2020)
Abstract Introduction Ixekizumab has demonstrated rapid onset of action, high levels of skin clearance, and improvements in quality of life in patients with moderate-to-severe psoriasis, including plaque, erythrodermic, or generalized pustular psoria
Externí odkaz:
https://doaj.org/article/22fbc0054777457194be6b7549b4bf76
Autor:
April W. Armstrong, Emily Edson-Heredia, April N. Naegeli, Russel Burge, Jiat-Ling Poon, Milena Anatchkova, Luna Sun, Baojin Zhu, Kathleen W. Wyrwich
Publikováno v:
Journal of Dermatological Treatment, Vol 31, Iss 5, Pp 452-459 (2020)
Background: Psoriasis is a chronic inflammatory skin disease. Objective: To establish content validity and assess psychometric properties of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis (Ps). Methods: The PSS is an
Externí odkaz:
https://doaj.org/article/57f067a063404671a6534ff99b4b7f69